{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-010093","form_type":"8-K","ticker":"SABS","cik":"0001833214","company_name":"SAB Biotherapeutics, Inc.","filed_at":"2024-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.844093+00:00","generated_at":"2026-06-06T10:03:33.688730+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Samuel J. Reich appointed CEO of SAB Biotherapeutics; remains Executive Chairman","bullets":["Reich expands role from Executive Chairman to CEO effective February 2, 2024.","Co-founder Eddie J. Sullivan continues as President and board member, leading operations and R&D.","Reich co-founded Biscayne Neurotherapeutics (sold to Supernus) and Acuity Pharmaceuticals.","Company advancing lead candidate SAB-142 for delaying type 1 diabetes progression."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-010093","json":"https://secwatch.observer/filing/0000950170-24-010093.json","markdown":"https://secwatch.observer/filing/0000950170-24-010093.md","text":"https://secwatch.observer/filing/0000950170-24-010093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/0000950170-24-010093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/sabs-20240130.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T10:03:33.688730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c2cc1e83a","claim":"Samuel J. Reich was appointed as Chief Executive Officer at SAB Biotherapeutics, Inc..","evidence_excerpt":"On January 30, 2024, Samuel J. Reich, age 49, the Executive Chairman of the Board of Directors (the “Board”) of SAB Biotherapeutics, Inc. (the “Company”), was appointed Chief Executive Officer of the Company, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1833214/000095017024010093/0000950170-24-010093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}